Despite poor growth, the company's high P/S ratio indicates investor hope for a business turnaround. If medium-term revenue trends persist, the share price may drop significantly, risking shareholder investments and potential investors paying a high premium.
Nanjing Hicin Pharmaceuticalに関するコメント
まだコメントはありません